SCHEMBL1800569

SCHEMBL1800569

CC(=O)NCc1ccc(N)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.63
HDAC1 Q13547 4/20 0.59
HDAC6 Q9UBN7 2/20 0.59
ALDH1A1 P00352 1/20 0.58
POLB P06746 1/20 0.58
MAPT P10636 1/20 0.58
RAB9A P51151 1/20 0.58
EPHX2 P34913 1/20 0.56
PPIB P23284 2/20 0.53
PPID Q08752 2/20 0.53
PPIA P62937 1/20 0.53
PPIG Q13427 1/20 0.53
KIF11 P52732 1/20 0.51
HDAC3 O15379 3/20 0.50
HDAC2 Q92769 3/20 0.50
EPHX1 P07099 1/20 0.50
HDAC4 P56524 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC7 Q8WUI4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10744056 0.98 KMT2A (0.61) KMT2AHDAC1HDAC6ALDH1A1POLB
SCHEMBL12133623 0.89 KMT2A (0.76) KMT2AHDAC1HDAC6ALDH1A1POLB
SCHEMBL5945697 0.87 KMT2A (0.50) KMT2AHDAC1HDAC6ALDH1A1POLB
Aniline SCHEMBL27372056 0.85 CYP2C9 (0.56) KMT2AHDAC1HDAC6ALDH1A1POLB
SCHEMBL24541407 0.84 KMT2A (0.59) KMT2AHDAC1HDAC6ALDH1A1POLB
SCHEMBL8404729 0.83 TPSAB1 (0.68) KMT2AHDAC1HDAC6ALDH1A1POLB
SCHEMBL5945692 0.83 EPHX2 (0.59) KMT2AHDAC1HDAC6ALDH1A1POLB
SCHEMBL15939528 0.83 PPID (0.65) KMT2AEPHX2PPIBPPIDPPIA
SCHEMBL258716 0.83 CYP2C9 (0.62) KMT2AALDH1A1MAPTEPHX2PPIB
SCHEMBL6415716 0.81 EPHX2 (0.50) KMT2AHDAC1HDAC6ALDH1A1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors ASTEX TECHNOLOGY, INC. (GB) 2006-06-22 US claimed
JP-2006500348-A 2006-01-05 JP claimed
EP-1534685-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS Astex Technology Limited (GB) 2005-06-01 EP claimed
WO-2004014864-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-02-19 WO claimed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 US disclosed
US-20170253614-A1 HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) 2017-09-07 US disclosed
EP-2788359-B1 COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS RES TRIANGLE INST (US) 2017-03-01 EP disclosed
US-9187453-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-17 US disclosed
US-9150582-B2 Composition and method for neuropeptide S receptor (NPSR) antagonists RESEARCH TRIANGLE INSTITUTE (US) 2015-10-06 US disclosed
CN-102459165-B Antiviral compound ABBVIE (US) 2015-09-02 CN disclosed
EP-1224170-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT Boehringer Ingelheim Pharma KG (DE) 2002-07-24 EP disclosed
WO-2001027081-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-04-19 WO disclosed
EP-0418385-B1 BENZOTRIAZOLE DERIVATIVES AND REAGENTS CONTAINING SAME FOR ANALYZING CARBOXYLIC ACIDS SHIONOGI & CO (JP) 1994-08-24 EP disclosed
US-5097040-A Existing as metabolites of carbohydrates, lipids, proteins SHIONOGI & CO., LTD. (JP) 1992-03-17 US disclosed
EP-0418385-A1 BENZOTRIAZOLE DERIVATIVES AND REAGENTS CONTAINING SAME FOR ANALYZING CARBOXYLIC ACIDS SHIONOGI & CO., LTD. (JP) 1991-03-27 EP disclosed
EP-0038453-B1 PROCESS FOR THE PREPARATION OF WATER SOLUBLE PHTHALOCYANINE DYESTUFFS BAYER AG (DE) 1983-05-25 EP disclosed
EP-0038453-A2 Process for the preparation of water soluble phthalocyanine dyestuffs BAYER AG (DE) 1981-10-28 EP disclosed
US-4010200-A FOR DYEING LIVE HUMAN HAIR SOCIETE ANONYME DITE: L'OREAL (FR) 1977-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253614-A1 HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS HAVCR2, HCCS, LIPC KMT2A 4575/4885HDAC1 1903/4885HDAC6 193/4885
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 KMT2A 1669/4885HDAC1 52/4885HDAC6 56/4885
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors CCNC, CDK1, CDK7 KMT2A 1773/4885HDAC1 318/4885HDAC6 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.